Lung cancer screening outcomes and cost-effectiveness analysis among community residents in Ma'anshan City from 2020 to 2024

YOU Zhongxiang; TANG Xingyu; SUN Guoqiang; WANG Na; QIN Qirong; HUANG Fen

doi:10.16462/j.cnki.zhjbkz.2025.07.015

Volume 29 Issue 7

Jul. 2025

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2025 > 29(7): 850-853

YOU Zhongxiang, TANG Xingyu, SUN Guoqiang, WANG Na, QIN Qirong, HUANG Fen. Lung cancer screening outcomes and cost-effectiveness analysis among community residents in Ma'anshan City from 2020 to 2024[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(7): 850-853. doi: 10.16462/j.cnki.zhjbkz.2025.07.015

Citation:

YOU Zhongxiang, TANG Xingyu, SUN Guoqiang, WANG Na, QIN Qirong, HUANG Fen. Lung cancer screening outcomes and cost-effectiveness analysis among community residents in Ma'anshan City from 2020 to 2024[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(7): 850-853. doi: 10.16462/j.cnki.zhjbkz.2025.07.015

Citation:

YOU Zhongxiang, TANG Xingyu, SUN Guoqiang, WANG Na, QIN Qirong, HUANG Fen. Lung cancer screening outcomes and cost-effectiveness analysis among community residents in Ma'anshan City from 2020 to 2024[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(7): 850-853. doi: 10.16462/j.cnki.zhjbkz.2025.07.015

PDF( 782 KB)

Lung cancer screening outcomes and cost-effectiveness analysis among community residents in Ma'anshan City from 2020 to 2024

doi: 10.16462/j.cnki.zhjbkz.2025.07.015

1.
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei 230032, China
2.
Department of Chronic Disease Prevention and Health Management, Ma'anshan Center for Disease Control and Prevention, Ma 'anshan 243000, China

Funds:

The Central Government Guides the Local Science and Technology Development Special Project of Anhui Province 202007d07050008

More Information

Corresponding author: HUANG Fen, E-mail: fenh@ahmu.edu.cn
Received Date: 2025-03-05
Rev Recd Date: 2025-05-06

Available Online: 2025-08-11

Publish Date: 2025-07-10

Abstract

Abstract

Objective To analyze the outcomes and cost-effectiveness of lung cancer screening in Ma′anshan City, Anhui Province, China, from 2020 to 2024, and to provide evidence for optimizing screening strategies and health policies. Methods Based on screening data, we evaluated the high-risk rate, compliance rate, and positive lesion detection rate among community residents aged 50-74 years. Cost-effectiveness ratio (CER), and early detection cost index (EDCI) were calculated. Results Among 13 542 participants, 4 547 individuals were identified as high-risk (high-risk rate: 33.58%). Of these, 2 903 (compliance rate: 63.84%) underwent low-dose computed tomography (LDCT). The total screening cost was CNY 1 168 001, with a cost per detected positive nodule of CNY 2 115.94 and per suspected lung cancer case of CNY 40 275.90. The CER was CNY 13 23.61, and the overall EDCI was 0.36. The 70-74 age group exhibited the lowest EDCI (0.19). Conclusions LDCT screening in high-risk populations demonstrates cost-utility value, particularly in the 70-74 age group. Future strategies should prioritize gender-and age-specific optimization to enhance screening efficiency.
- Lung cancer,
- Screening,
- Low-dose computed tomography,
- Cost-effectiveness analysis

FullText(HTML)

References(15)

References

[1]	Han BF, Zheng RS, Zeng HM, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.
[2]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[3]	Lancaster HL, Heuvelmans MA, Oudkerk M. Low-dose computed tomography lung cancer screening: clinical evidence and implementation research[J]. J Intern Med, 2022, 292(1): 68-80. DOI: 10.1111/joim.13480.
[4]	Lam S, Bai CX, Baldwin DR, et al. Current and future perspectives on computed tomography screening for lung cancer: a roadmap from 2023 to 2027 from the international association for the study of lung cancer[J]. J Thorac Oncol, 2024, 19(1): 36-51. DOI: 10.1016/j.jtho.2023.07.019.
[5]	国家卫生健康委员会医疗应急司. 肺癌筛查与早诊早治方案(2024年版)[J]. 中华肿瘤杂志, 2024, 46(10): 911-912. DOI: 10.3760/cma.j.cn112152-20240828-00373. Medical Emergency Department, National Health Commission of China. Lung cancer screening and early diagnosis/treatment protocol (2024 version)[J]. Chin J Oncol, 2024, 46(10): 911-912. DOI: 10.3760/cma.j.cn112152-20240828-00373.
[6]	马鞍山市统计局. 2024年马鞍山市统计年鉴[M]. 马鞍山: 马鞍山市统计局, 2024: 51. Ma'anshan City Bureau of Statistics. Ma'anshan statistical yearbook 2024[M]. Ma'anshan: Ma'anshan City Bureau of Statistics, 2024: 51.
[7]	田田, 魏东华, 徐叶红, 等. 2015-2019年合肥市城市居民肺癌筛查结果分析[J]. 中华肿瘤防治杂志, 2022, 29(23): 1653-1658. DOI: 10.16073/j.cnki.cjcpt.2022.23.03. Tian T, Wei DH, Xu YH, et al. Analysis of lung cancer screening for urban residents in Hefei from 2015 to 2019[J]. Chin J Cancer Prev Treat, 2022, 29(23): 1653-1658. DOI: 10.16073/j.cnki.cjcpt.2022.23.03.
[8]	杨庆, 刘德, 娄培安, 等. 2014-2019年徐州市城市居民肺癌筛查结果及成本-效果分析[J]. 中华肿瘤防治杂志, 2022, 29(7): 463-467. DOI: 10.16073/j.cnki.cjcpt.2022.07.03. Yang Q, Liu D, Lou PA, et al. Results and cost-effectiveness analysis of lung cancer screening for urban residents in Xuzhou from 2014 to 2019[J]. China J Cancer Prev Treat, 2022, 29(7): 463-467. DOI: 10.16073/j.cnki.cjcpt.2022.07.03.
[9]	张旭, 华婧, 范康琼, 等. 2019—2021年海南省海口市45~74岁城市居民肺癌筛查结果及成本-效果分析[J]. 中国肿瘤, 2024, 33(6): 492-497. DOI: 10.11735/j.issn.1004-0242.2024.06.A011. Zhang X, Hua J, Fan KQ, et al. Results of lung cancer screening among urban residents aged 45~74 years old in Haikou City from 2019 to 2021 and cost-effectiveness analysis[J]. China Cancer, 2024, 33(6): 492-497. DOI: 10.11735/j.issn.1004-0242.2024.06.A011.
[10]	de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung cancer mortality with volume ct screening in a randomized trial[J]. N Engl J Med, 2020, 382(6): 503-513. DOI: 10.1056/NEJMoa1911793.
[11]	Li N, Tan FW, Chen WQ, et al. One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study[J]. Lancet Respir Med, 2022, 10(4): 378-391. DOI: 10.1016/S2213-2600(21)00560-9.
[12]	Potter AL, Rosenstein AL, Kiang MV, et al. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study[J]. BMJ, 2022, 376: e069008. DOI: 10.1136/bmj-2021-069008.
[13]	赵曌, 芮媛媛, 刘勇, 等. 2018—2022年江西省南昌市城市癌症早诊早治项目筛查结果分析[J]. 中国肿瘤, 2023, 32(12): 917-924. DOI: 10.11735/j.issn.1004-0242.2023.12.A005. Zhao Z, Rui YY, Liu Y, et al. Analysis of screening results of urban cancer early detection and treatment program in Nanchang City from 2018 to 2022[J]. China Cancer, 2023, 32(12): 917-924. DOI: 10.11735/j.issn.1004-0242.2023.12.A005.
[14]	Liang D, Shi J, Li DJ, et al. Participation and yield of a lung cancer screening program in Hebei, China[J]. Front Oncol, 2022, 11: 795528. DOI: 10.3389/fonc.2021.795528.
[15]	范亚光, 周清华, 乔友林, 等. 中国肺癌低剂量CT筛查指南(2023年版)[J]. 中国肺癌杂志, 2023, 26(1): 1-9. DOI: 10.3779/j.issn.1009-3419.2023.102.10. Fan YG, Zhou QH, Qiao YL, et al. China national lung cancer screening guideline with low-dose computed tomography (2023 version)[J]. Chin J Lung Cancer, 2023, 26(1): 1-9. DOI: 10.3779/j.issn.1009-3419.2023.102.10.